{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:49:08Z","timestamp":1791244148364,"version":"4.1.0"},"reference-count":47,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Shanghai Municipal Health Commission project","award":["202240380"],"award-info":[{"award-number":["202240380"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Technol Cancer Res Treat"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>A subgroup of pancreatic cancer with unstable genome, such as BRCA mutation, may be more sensitive to platinum-based chemotherapy. How to define the patients with homologous recombination deficiency (HRD) status other than BRCA mutation has been a clinical challenge and interest.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective cohort study, we collected NGS data of 163 pancreatic cancer patients from July 2020 to April 2024. HRD score was calculated by 3DMed-HRD algorithm. The median of HRD score of our study population was used as potential cut-off value to determine HRD status. Cox regression was used to evaluate association of HRD status, platinum-based chemotherapy and overall survival (OS). Kaplan\u2013Meier method with log-rank test was performed to analyze OS among different subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 163 patients, the HRD score ranged from 0 to 76. The mean value was 10.48. The median was 6. With a criterion of HRD \u22656 and\/or germline Homologous Recombination Repair (HRR) mutation, a total of 89 patients were considered to be HRD+. HRD+ status was associated with a poor prognosis (HR: 1.46, 95%CI:1.01-2.11, p=0.04). Platinum-based all-time usage would reduce the hazard of death by 34% (HR: 0.66, 95%CI: 0.45-0.97, p=0.03). Among the HRD+ subjects, the initiation of platinum-based chemotherapy might be associated with a longer overall survival (OS: 19.92 vs 15.38, Log-Rank test, p=0.09).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>HRD score could be a potential indicator for genome unstable pancreatic cancer patients who would benefit from platinum derivatives. Future study with better design and larger population size would help to determine a proper threshold for clinical application.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/15330338261469099","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T11:54:01Z","timestamp":1784030041000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["HRD Score: A Promising Biomarker for Genomic Instability Evaluation for Targeted Treatments Among Pancreatic Cancer Patients"],"prefix":"10.1177","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9714-3467","authenticated-orcid":false,"given":"Xiaoyi","family":"Wang","sequence":"first","affiliation":[{"name":"Fudan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Fudan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yecheng","family":"Xu","sequence":"additional","affiliation":[{"name":"Fudan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenteng","family":"Miao","sequence":"additional","affiliation":[{"name":"Fudan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bai\u2019an","family":"Tao","sequence":"additional","affiliation":[{"name":"Fudan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Jin","sequence":"additional","affiliation":[{"name":"Fudan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1832-2000","authenticated-orcid":false,"given":"Deliang","family":"Fu","sequence":"additional","affiliation":[{"name":"Fudan University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"e_1_3_7_2_2","unstructured":"Institute NC. Surveillance Epidemiology and End Results Program. 2023. https:\/\/www.seer.cancer.gov. Accessed February 10th 2023."},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa004"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01366-1"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903387"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.02.012"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2021.06.027"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature14169"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7401"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0582-7"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-0628"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2015.21"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24865"},{"issue":"5","key":"e_1_3_7_15_2","first-page":"603","article-title":"NCCN Guidelines Updates: Pancreatic Cancer","volume":"17","author":"Tempero MA","year":"2019","unstructured":"Tempero MA. NCCN Guidelines Updates: Pancreatic Cancer. J Natl Compr Canc Netw. 2019;17(5.5):603-605.","journal-title":"J Natl Compr Canc Netw"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00261-2"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2017.12.021"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-015-0033-4"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3670"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gde.2020.05.028"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrg2529"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01924"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2022.0525"},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32853"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00087"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkh103"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0155"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061911"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02514"},{"key":"e_1_3_7_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00780-4"},{"key":"e_1_3_7_32_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2021.02.003"},{"key":"e_1_3_7_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-025-00637-4"},{"key":"e_1_3_7_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00620-7"},{"key":"e_1_3_7_35_2","unstructured":"Astellas Confirms Phase 2 GLEAM Trial Did Not Meet Primary Endpoint of Overall Survival in Patients with Metastatic Pancreatic Cancer. 2025.10.14. https:\/\/newsroom.astellas.com\/2025-10-13-Astellas-Confirms-Phase-2-GLEAM-Trial-Did-Not-Meet-Primary-Endpoint-of-Overall-Survival-in-Patients-with-Metastatic-Pancreatic-Cancer"},{"key":"e_1_3_7_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-020-00951-0"},{"key":"e_1_3_7_37_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733"},{"key":"e_1_3_7_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.02.014"},{"key":"e_1_3_7_39_2","article-title":"Identifying ARRB2 as a Prognostic Biomarker and Key Player in the Tumor Microenvironment of Pancreatic Cancer through scPagwas Methodology","author":"Tian G","year":"2025","unstructured":"Tian G, Liu C, Che C, et al. Identifying ARRB2 as a Prognostic Biomarker and Key Player in the Tumor Microenvironment of Pancreatic Cancer through scPagwas Methodology. Curr Gene Ther. 2025.","journal-title":"Curr Gene Ther"},{"key":"e_1_3_7_40_2","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2025.2570705"},{"key":"e_1_3_7_41_2","doi-asserted-by":"publisher","DOI":"10.2174\/0929866530666230213113835"},{"key":"e_1_3_7_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2026.102564"},{"key":"e_1_3_7_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad178"},{"key":"e_1_3_7_44_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1788"},{"key":"e_1_3_7_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2016.10.005"},{"key":"e_1_3_7_46_2","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/8962321"},{"key":"e_1_3_7_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-020-0549-5"},{"key":"e_1_3_7_48_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03238"}],"container-title":["Technology in Cancer Research &amp; Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15330338261469099","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15330338261469099","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15330338261469099","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:48:25Z","timestamp":1784260105000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15330338261469099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":47,"alternative-id":["10.1177\/15330338261469099"],"URL":"https:\/\/doi.org\/10.1177\/15330338261469099","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/15330338261469099\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338261469099\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338261469099\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338261469099\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338261469099\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338261469099\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338261469099\/v1\/decision1","asserted-by":"object"}]},"ISSN":["1533-0346","1533-0338"],"issn-type":[{"value":"1533-0346","type":"print"},{"value":"1533-0338","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"article-number":"15330338261469099"}}